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ABSTRACT
Glioblastoma (GB) is the most aggressive and lethal tumour of the
central nervous system (CNS). GB cells grow rapidly and display a
network of projections, ultra-long tumour microtubes (TMs), that
mediate cell to cell communication. GB-TMs infiltrate throughout the
brain, enwrap neurons and facilitate the depletion of the signalling
molecule wingless (Wg)/WNT from the neighbouring healthy
neurons. GB cells establish a positive feedback loop including Wg
signalling upregulation that activates cJun N-terminal kinase (JNK)
pathway and matrix metalloproteases (MMPs) production, which in
turn promote further TMs infiltration, GB progression and
neurodegeneration. Thus, cellular and molecular signals other than
primary mutations emerge as central players of GB. Using a
Drosophila model of GB, we describe the temporal organisation of
the main cellular events that occur in GB, including cell-to-cell
interactions, neurodegeneration and TM expansion. We define the
progressive activation of JNK pathway signalling in GB mediated by
the receptor Grindelwald (Grnd) and activated by the ligand Eiger
(Egr)/TNFα produced by surrounding healthy brain tissue. We
propose that cellular interactions of GB with the healthy brain tissue
precede TM expansion and conclude that non-autonomous signals
facilitate GB progression. These results contribute to deciphering the
complexity and versatility of these incurable tumours.
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INTRODUCTION
Glioblastoma multiforme (GB) is the most frequent and aggressive
primary malignant brain tumour, with an incidence of three per
100,000/year (Gallego, 2015). GB patients’ median survival is
12–15 months, with less than 5% chance of survival after 5 years
(Gallego, 2015; Louis et al., 2016; McGuire, 2016; Rogers et al.,
2018). The causes of GB are under debate (McGuire, 2016), 5% of
the patients develop GB after a low grade astrocytoma (Alifieris and
Trafalis, 2015) and the most frequent mutations include gain of
function of the epidermal growth factor receptor (EGFR) (97%) and
the phosphatidylinositol-3 kinase (PI3K)/phosphatase and tensin
homologue (PTEN) pathways (88%) (Hayden, 2010). The
diagnosis, and therefore the treatment of GB, requires a mutation
analysis taking into account the high frequency of clones within the
same primary GB (Wick et al., 2018). Temozolomide (TMZ) is the
only treatment for GB, however, recent discoveries restrict the use of
TMZ in GB patients depending on the methylation status of
methylguanine DNA methyltransferase (MGMT) (Wick et al.,
2018). Moreover, among other mutations, Isocitrate dehydrogenase
(IDH) defines the nature and features of GB (Waitkus et al., 2018)
together with molecular alterations including 1p/10q deletions and
tumour suppressor protein 53 (TP53) and alpha thalassemia/
mental retardation (ATRX) mutations (Miller et al., 2017; Waitkus
et al., 2018). The genetic and molecular heterogeneity complicate
the diagnosis and treatment of these fatal brain tumours.
EGFR mutant forms show constitutive kinase activity that
chronically stimulates Ras signalling to drive cell proliferation and
migration (Furnari et al., 2007; Maher et al., 2001). Other common
genetic lesions include loss of the lipid phosphatase PTEN, which
antagonises the PI3K signalling pathway, and mutations that activate
PI3KCA,which encodes the p110a catalytic subunit of PI3K (Furnari
et al., 2007; Maher et al., 2001). GBs often show constitutively active
Akt, amajor PI3K effector.Multiple mutations that coactivate EGFR-
Ras and PI3K/Akt pathways are required to induce a glioma
(Holland, 2000). In Drosophila, a combination of EGFR and PI3K
mutations effectively causes a glioma-like condition that reproduces
the features of human gliomas including glia expansion, brain
invasion, neuron dysfunction, synapse loss and neurodegeneration.
This model involves the co-overexpression of constitutively active
forms of EGFR (dEGFRλ) and an activated membrane-localised
version of the PI3K catalytic subunit p110α/PI3K92E
(dPI3K92ECAAX) under Gal4 UAS control, specifically driven in
the glial cells by means of repo-Gal4 (Brand and Perrimon, 1993;
Casas-Tintó et al., 2017; Read et al., 2009).
The recent discovery of a network of ultra-long tumour
microtubes (TMs) in GB (Osswald et al., 2015), also known as
cytonemes in Drosophila (Casas-Tintó and Portela, 2019),
improves our understanding of GB progression and therapy
resistance (Osswald et al., 2016). In GB, this network of TMs
mediates cell-to-cell communication. TMs are actin-based filopodia
that infiltrate into the brain and reach long distances within the brain
(Osswald et al., 2015). TMs are required in GB cells to mediate
Wingless (Wg)/WNT signalling imbalance among neurons and GB
cells. Wg/WNT signalling is increased in GB cells to promote
tumoural progression, at the expense of neuronal Wg signalling,
which results in neurodegeneration and lethality (Arnés and Casas
Tintó, 2017; Casas-Tintó and Portela, 2019; Portela et al., 2019).
Another recent study has shown that GB produces ImpL2, an
antagonist of the insulin pathway that targets neighbouring neurons
and causes mitochondrial disruption as well as synapse loss. Rheb
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pathway, prevents mitochondrial disruption as well as synapse loss
and the reduction in life span caused by GB (Jarabo et al., 2020).
The central role of TMs in GB biology has emerged as a
fundamental mechanism for GB rapid and lethal progression; thus,
it is an attractive field of study towards potential GB treatments.
However, the molecular mechanisms underlying the expansion of
TMs and the signalling pathways mediating TM infiltration are still
poorly understood.
The Jun-N-terminal Kinase (JNK) pathway is a hallmark of GB
cells that is associated to glial proliferation and stem-like status, and
currently it is a pharmacological target for GB (Matsuda et al.,
2012). Moreover, the JNK pathway is the main regulator of matrix
metalloproteases (MMPs) expression and cell motility in many
organisms and tissues including tumours like GB (Cheng et al.,
2012; Ispanovic and Haas, 2006; Lee et al., 2009; Portela et al.,
2019; Uhlirova and Bohmann, 2006; Zeigler et al., 1999).
MMPs are a family of endopeptidases capable of degrading
the extracellular matrix (ECM).Members of theMMP family include
the ‘classical’MMPs, the membrane-boundMMPs (MT-MMPs), the
ADAMs (a disintegrin and metalloproteinase; adamlysins) and the
ADAMTS (a disintegrin andmetalloproteinasewith thrombospondin
motif). There are more than 20 members in the MMP and ADAMTS
family including the collagenases, gelatinases, stromelysins, some
elastases and aggrecanases (Malemud, 2006). The vertebrate MMPs
have genetic redundancy and compensation, they have overlapping
substrates, and pharmacological inhibitors are non-specific. There are
two orthologues to humanMMPs inDrosophila,MMP1 andMMP2.
MMP1 is secreted and MMP2 is membrane-anchored (Page-McCaw
et al., 2003). However, recent reports propose that products of both
genes are found at the cell surface and released into media, and that
GPI-anchored MMPs promote cell adhesion when they become
inactive. Moreover, the two MMPs cleave different substrates,
suggesting that this is the important distinction within this small
MMP family (LaFever et al., 2017). MMPs are upregulated in several
tumours, including GBs. Cancer cells produce MMPs to facilitate
tumour progression and invasiveness and MMPs upregulation in GB
is associated with the diffuse infiltrative growth and have been
proposed to play a role in GB cell migration and infiltration (de Lucas
et al., 2016; Veeravalli and Rao, 2012; reviewed in Nakada et al.,
2003). MMPs are upregulated in human GB cell-lines and biopsies as
compared with low-grade astrocytoma (LGA) and normal brain
samples (Hagemann et al., 2012, 2010). In particular, among the 23
MMPs present in humans, MMP9, MMP2 and MMP14 are directly
implicated in growth and invasion of GB cells (Munaut et al., 2003).
WNT induces MMPs expression during development and cancer
(Lowy et al., 2006; Lyu and Joo, 2005; Page-McCaw et al., 2003;
Roomi et al., 2017; Uraguchi et al., 2004) associated to cell
migration and metastasis. Specifically, in human GB, MMP2
expression and their infiltrative properties correlate with Wnt5
(Kamino et al., 2011; Roth et al., 2000) and MMP9 is upregulated
upon EGFR activity (Chen et al., 2016).
In consequence,MMPs upregulation in GB is an indicator of poor
prognosis (Yamamoto et al., 2002) and the study of the mechanisms
mediated by MMPs is relevant for the biology of GB, and cancer in
general. GB cells project TMs that cross the ECM and infiltrate in
the brain to reach territories distant from the primary GB site
(Osswald et al., 2015, 2016). We have previously demonstrated that
GB cells activate the JNK pathway and accumulate MMPs (MMP1
and 2). MMPs contribute to TMs expansion in the brain and
facilitate Wg/WNT signalling in GB cells through the receptor
Frizzled1 (Fz1). Moreover, Wg/WNT signalling mediates JNK
activation in GB cells to continue with MMPs production and TMs
infiltration process. We hypothesise that the founder mutations in
GB (PI3K and EGFR) initiate the process with the expansion of the
TMs; afterwards, the system self-perpetuates (TMs-Fz1/Wg-JNK-
MMPs-TMs) to facilitate GB progression and infiltration in the
brain (Portela et al., 2019).
We have recently shown that JNK pathway activation mediated
by the receptor Grnd is a requirement for GB progression, TMs
expansion and Fz1-mediated Wg depletion from neurons. In turn,
Wg pathway upregulation in GB induces JNK activity in GB
cells that mediate the production of MMPs. Moreover, MMPs
knockdown in GB cells is sufficient to rescue neurodegeneration
and premature death caused by GB (Portela et al., 2019). However,
the molecular mechanisms by which JNK pathway is activated in
GB cells remain unknown.
Here, we investigated the mechanism by which the JNK
signalling pathway is activated in GB cells. Egr activates the JNK
pathway in GB cells through the specific receptor Grnd,
highlighting again the contribution of communication signals
between healthy brain tissue and GB cells to the progression of
the disease (Jarabo et al., 2020; Portela et al., 2019). Through
transcriptional and immunofluorescence analysis of Egr in GB, we
found that Egr localises mostly into the brain tissue that includes
neurons and neuroblasts, and a smaller fraction of Egr is present in
healthy glial cells. However, in GB brains there is a shift of Egr from
the surrounding healthy tissue towards GB cells. These results
suggest that Egr is expressed by non-tumoural brain tissue, but it is
accumulated in tumoural cells and activates the JNK pathway. In
consequence, GB cells produce MMPs that facilitate TM infiltration
and GB progression. At the cellular level, we analyse three aspects
required for GB progression: TMs expansion, GB cell number
increase and synapse loss in the surrounding neurons and propose a
timeline for these events in GB progression.
RESULTS
Combined activation of EGFR and PI3K pathways is required
for GB progression
The Drosophila GB model reproduces the main features of the
disease including the expansion of TMs. Cytonemes and TMs share
multiple features (Casas-Tintó and Portela, 2019; Portela et al.,
2019) and can be visualised with green/red fluorescent membrane
tags (e.g. CD8-GFP or myr-RFP), or cytoneme components
including signalling proteins such as Ihog (Ihog-RFP). Membrane
markers are expressed under the control of the glial specific
enhancer repo-Gal4 (Casas-Tintó et al., 2017). Therefore, only glial
cells are marked with RFP (red), and in the Drosophila brain the
unlabelled surrounding cells are mostly neuroblasts and neurons that
are marked with the neuron specific antibody anti-horseradish
peroxidase (Hrp) in green (Fig. S1A) (Portela et al., 2019).
WNT signalling is a hallmark in gliomagenesis associated with
the proliferation of stem-like cells in human GBs (Kahlert et al.,
2015). We have previously shown that GB cells expand a network of
TMs that accumulate the Wg receptor Fz1, and deplete Wg from the
surrounding neurons, a mechanism that leads to activation of Wg
signalling in these tumoural cells (Portela et al., 2019).
Concomitant activation of both PI3K and EGFR signalling
pathways is necessary to induce a glioma (Read et al., 2009). First,
we sought to clarify the separate contribution of PI3K and EGFR
signalling pathways to GB progression, and the associated
phenotypes including Wg/Fz1 abnormal distribution and
signalling activation in GB cells. Fz1 localisation in the TMs is
key to trigger Wg signalling and GB cell number increase. We first
induced constitutive activation of EGFR or PI3K/PTEN pathways
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independently in glial cells, and using conventional
immunofluorescence staining, we assessed the presence of Fz1
receptor in glial membranes with a specific monoclonal antibody
previously validated (Portela et al., 2019). Fz1 receptor signal is
localised homogeneously across the brain in control samples
(Fig. S1B). However, in the GB model (PI3K+EGFR), Fz1
accumulates in TMs (Fig. S1C) (Portela et al., 2019). To
determine if expression of constitutively active forms of PI3K or
EGFR independently is sufficient to trigger TMs network
expansion and Fz1 localisation in the TMs, we expressed
Drosophila PI3K or EGFR (UAS-dp110CAAX or UAS-TOR-
DERCA) in glial cells driven by repo-Gal4 and stained with Fz1
antibody. The results show that Fz1 receptor signal is localised
homogeneously across the brain (Fig. S1D,E) similar to control
samples, and the glial TM network does not expand as in GB
(compare Fig. S1D,E to Fig. S1B,C), although there are some
morphological differences in the glial membranes upon EGFR
overexpression compared to the control (Fig. S1B,E). These data
suggest that the activation of both pathways together is necessary for
the expansion of the TMs network and Fz1 localisation in the TMs.
PI3K and EGFR pathways converge in dMyc expression and
dMyc expression is required for GB development (Annibali et al.,
2014; Read et al., 2009; Tateishi et al., 2016; Wang et al., 2017).
Thus, to determine if dMyc is sufficient to trigger TMs network and
activate the Wg pathway, we ectopically overexpressed dMyc (UAS-
dMyc) in glial cells that are labelled with ihog-RFP (repo-Gal4), and
stained the brains with anti-Fz1 to detect theWg receptor (Fig. S1F),
or anti-Wg to detect the ligand Wg (Fig. S1G–I). Wg targets are
indicators of Wg/Fz1 activity in the recipient cell. Armadillo/β-
Catenin is a cytoplasmic protein which, upon activation of Wg
pathway, translocates into the nucleus and activates transcription of
target genes (Arnés and Casas Tintó, 2017; Klaus and Birchmeier,
2008). To determine whether ectopic overexpression of dMyc in
glial cells is sufficient to trigger Wg/Fz1 signalling in GBs, we used
an anti-Armadillo (Arm) antibody, which identifies its cytoplasmic
inactive form (Cyt-Arm; Portela et al., 2019) (Fig. S1J–L). The
confocal images show no morphological evidence of GB formation
(Fig. S1F compare to GB in Fig. S1C). Moreover, Fz1, Wg or
Cyt-Arm protein distribution resemble control brains (Fig. S1B,F,G,
I,J,L). Taking these results together, we conclude that dMyc
overexpression is not sufficient to reproduce the features of the GB.
These results suggest that upregulation of both PI3K and EGFR
signalling pathways in glial cells is necessary for the expansion of
glial TMs, Fz1 localisation in TMs and activation of the Wg
pathway to reproduce GB features.
We have previously shown that MMPs are upregulated in the
Drosophila model of GB and that the TM infiltration through the
brain is mediated by their activity (Portela et al., 2019). Next, we
explored if the independent activation of EGFR or PI3K is sufficient
to induce the upregulation ofMMPs and the epistatic relations behind
MMPs upregulation. To determineMMP production and localisation,
we used a specific monoclonal antibody against Drosophila MMP1.
The confocal images show that MMP1 is homogeneously distributed
across the brain in control samples with a slight accumulation in the
Ihog+ projections (Fig. 1A), and the quantifications revealed an
increase in the MMP1 glia/neuron ratio in the TMs of GB samples
(Fig. 1B). Consistent with the results shown above, MMP1 shows a
homogeneous distribution through the brain, also with a slight
accumulation in the Ihog+ projections, upon constitutive activation of
PI3K (dp110CAAX) or EGFR (TOR-DERCA) in glial cells (Fig. 1C,D,
quantified in F), comparable to the controls (Fig. 1A). Besides, dMyc
overexpression in glial cells did not cause significant changes in
MMPs localisation (Fig. 1E,F). Taking these results together,
independent overexpression of EGFR, PI3K or dMyc is not
sufficient to reproduce the features of GB. These results suggest
that the combined activity of PI3K and EGFR pathways are necessary
to activate a downstream pathway responsible for the expansion of
TMs andMMP1 accumulation in GB cells; and dMyc overexpression
is not sufficient to cause these phenotypes.
Non-autonomous activation of JNK pathway in GB
In addition to Wg pathway, GB cells activate JNK pathway to
maintain the stem-like cells, which has become a pharmacological
3
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target for the treatment of GB (Matsuda et al., 2012). Moreover, we
have previously shown that JNK signalling activation, mediated by
the receptor Grnd, is necessary in GB cells for TMs expansion and
tumour progression (Portela et al., 2019). However, the specific
mechanism of Grnd receptor activation is still unknown. A recent
study using gene-expression profiling identified genes that were
correlated significantly with the overall survival of patients with GB
(Hsu et al., 2019). 104 genes were identified, which are common
between patients with GB and those with low grade gliomas and can
be used as core genes related to patient survival. Of these, ten genes
(CTSZ, EFEMP2, ITGA5, KDELR2, MDK, MICALL2, MAP 2
K3, PLAUR, SERPINE1 and SOCS3) can potentially classify
patients with gliomas into different risk groups. Among these
pathways, the TNF-α signalling pathway stands out. Four genes
from this ten-gene group (MAP 2 K3, PLAUR, SERPINE1 and
SOCS3) are involved in TNFα signalling, and they might have
potential prognostic value for patients with GB (Hsu et al., 2019).
TNF-like weak inducer of apoptosis (TWEAK, also known as
TNFSF12) is a ligand of the TNF family (Chicheportiche et al.,
1997). TNFSF12 preferentially activates non-canonical NF-κB and
promotes the invasive properties of glioma cells (Cherry et al.,
2015). To determine the contribution of TNFSF12 to GB, we
analysed the data from The Cancer Genome Atlas (TCGA) dataset
from GlioVis (http://gliovis.bioinfo.cnio.es/). In silico analysis
showed that TNFSF12 gene is highly upregulated in several
samples of CNS tumours, including GB (grade IV) (Fig. 2A).
Accordingly, TNFSF12 expression has a negative implication to the
overall survival of patients with gliomas (Fig. 2B).
Due to the relevance of JNK pathway and TNFα ligand in GB
prognosis and progression, and to provide mechanistic insight into
how the JNK pathway and MMPs are activated in GB and whether
this is an autonomous or non-autonomous regulatory mechanism,
we decided to study Egr, the solely Drosophila orthologue of the
ligand for the mammalian TNF receptor signalling pathway (Igaki
et al., 2002; Moreno et al., 2002) and its receptor Grnd (Andersen
et al., 2015), in the Drosophila GB model.
Egr re-localises from neurons to glia in GB
Next, we investigated whether Egr, a ligand of JNK pathway, is
involved in in GB progression. We first assessed Egr protein
localisation. To monitor Egr protein distribution, we used a
previously validated transgenic Drosophila line (Doupé et al.,
2018) which carries a transposon insertion that leads to a protein
fusion of endogenous Egr tagged with GFP (Nagarkar-Jaiswal et al.,
2015; Doupé et al., 2018). The results from confocal microscopy
show that 70% of Egr-GFP signal is localised in the tissue
surrounding the glial cells and 30% of Egr-GFP signal is localised in
the glia (Fig. 2C,D and H). However, in GB samples there is a shift
of Egr-GFP signal from the surrounding tissue towards glial cells
(∼50%) (Fig. 2E–H). We validated the Egr-GFP fusion protein with
anti-MMP2 staining as a target of the JNK pathway in glial cells
(Portela et al., 2019). The confocal images show that GFP signal
coincides with MMP2 signal, suggesting that Egr-GFP is a
functional tool (Fig. S2A). Next, we monitored the expression
pattern of the JNK receptor Grnd in GB and control samples, with a
specific antibody previously validated (Andersen et al., 2015). The
quantification of Grnd signal shows an increase of Grnd protein in
the membrane of GB cells (Fig. 2I–K). The abnormal distribution of
Egr and Grnd in GB brains could be due to either an increase in gene
expression or to redistribution of the proteins. To determine the
expression levels of grnd and egr, we undertook quantitative
polimerase chain reaction (qPCR) experiments with RNA extracted
from control and GB larvae brains, which revealed a twofold
increase of egr transcription in GB brains compared to controls
(Fig. 2L) consistent with the increased Egr signal in glioma brains,
and no significant differences for grnd transcription.
Egr expressed in healthy tissue activates JNK in GB
The qPCR results that show transcriptional upregulation of egr in
GB brains were obtained from whole brains extracts, therefore we
cannot determine which specific cells upregulate egr. To determine
whether the source of Egr is the glia, we silenced egr expression
specifically in glioma cells. We used two different RNAi lines to
knockdown egr (egr-RNAi) in GB cells (repo>dp110CAAX; EGFRλ;
egr-RNAi). These two UAS-egr-RNAi lines have been previously
validated, egr-RNAi 2 (Perkins et al., 2015) and egr-RNAi 3
(Beira et al., 2018; Doupé et al., 2018; Igaki et al., 2002). The
quantifications show that egr knockdown in GB cells, does not
prevent GB cell number increase (Fig. 3A–D and E) nor GB TMs
expansion (Fig. 3A–D and F). Next we used a somatic mutant allele
in homozygosis, egr[MI15372] (Nagarkar-Jaiswal et al., 2015; Portela
et al., 2019), to knockout egr expression in the whole animal,
including GB cells and surrounding healthy tissue (denoted egr−/−).
The analysis of confocal images indicates that the elimination of Egr
prevents GB cell number increase (Fig. 3E–G) and TM volume
expansion (Fig. 3F and H).
Together, our results show an increase of Egr protein in GB TMs
(Fig. 2), however, egr expression in GB cells is not relevant for GB
progression. Nevertheless, egr knockout prevents GB progression.
Consistently, egr knockout phenocopies the effects of blocking
JNK pathway signalling, via grnd knockdown or by expressing a
dominant negative form of the effector Bsk (BskDN) (Adachi-
Yamada et al., 1999) in GB cells.
Next, to determine if Egr produced in neurons is capable of
activating the JNK pathway in neighbouring glial cells, we
overexpressed egr under the control of the specific neuronal
lineage driver dnab-Gal4 (Fig. S2B) and monitored JNK activity
with a standard JNK reporter [ puckered (puc)-LacZ]. This construct
monitors the transcriptional activation of the downstream JNK
target puckered (Langen et al., 2013; Martin-Blanco et al., 1998).
The confocal images of brain samples show neuronal lineages
labelled with CD8-GFP (green) and the neuron-specific marker
anti-ELAV (red), and intercalated glial cells stained with anti-Repo
Fig. 1. Independent constitutive activation of PI3K or EGFR or ectopic
dmyc are not responsible for MMP1 accumulation in GB. Brain sections
from third-instar larvae displayed at the same scale. Glia are labelled with
UAS-ihog-RFP (gray or red in the merge) driven by repo-Gal4 to visualise
active cytonemes/ TM structures in glial cells and stained with MMP1 (gray
or green in the merge). (A) MMP1 (gray or green in the merge) is
homogeneously distributed in control sections, with a slight accumulation in
the cytonemes. (B) In Glioma brains, MMP1 accumulates in the TMs and
specifically in the TM projections that are in contact with the neuronal
clusters. (C–E) MMP1 (gray or green in the merge) is homogeneously
distributed in (C) dp110CAAX, (D)TOR-DERCA and (E) dmyc sections with a
slight accumulation in the cytonemes similar to controls. Nuclei are marked
with DAPI (blue). (F) Quantification of MMP1 staining ratio between ihog+
and ihog– domains. Data from three independent experiments, n>10
samples analysed for each genotype per experiment. Kruskal–Wallis test
with Dunn’s post-hoc test. Error bars show mean±s.d.; ***P<0.0001 or ns for
non-significant. Scale bar size is indicated in all figures. The expression
system was active, and the GB induced, during the whole development
including both embryonic and larval stages in all experiments in this figure.
Genotypes: (A) UAS-lacZ/repo-Gal4, UAS-ihog-RFP; (B) UAS-dEGFRλ,
UAS-dp110CAAX;; repo-Gal4, UAS-ihog-RFP; (C) UAS-dp110CAAX;; repo-
Gal4, UAS-ihog-RFP; (D) UAS-TOR-DERCA;; repo-Gal4, UAS-ihog-RFP;
(E) repo-Gal4, UAS-ihog-RFP/UAS-dmyc.
4









 by guest on January 19, 2021http://bio.biologists.org/Downloaded from 
(blue) (Fig. S2B). Under normal conditions, (Fig. S2C), puc-LacZ
reporter revealed that the JNK pathway activity is moderated in brain
cells. However, upon egr overexpression in neurons, the JNK
pathway reporter is activated in both neurons and in the surrounding
glial cells (Fig. S2D,E). These results indicate that egr
overexpressed in neurons can activate the JNK pathway in the
surrounding glial cells.
Thus, we propose that the surrounding healthy brain tissue is the
source of Egr, which in a GB condition progressively relocates to
the GB TMs and activate JNK signalling through Grnd.
Progressive JNK activation in glioma
The JNK pathway is upregulated in a number of tumours including
GB and it is related to glioma malignancy (Hagemann et al., 2005;
Huang et al., 2003; Mu et al., 2018; Zeng et al., 2018). Moreover,
JNK is a target for specific drugs in combination with TMZ
treatments as it was proven to play a central role in GB progression
(Feng et al., 2016; Kitanaka et al., 2013; Matsuda et al., 2012;
Okada et al., 2014). However, little is known about the molecular
mechanisms underlying JNK activation in GB cells and the
functional consequences for GB progression.
Fig. 2. See next page for legend.
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We have previously shown that the JNK pathway is activated in
Drosophila GB cells (Portela et al., 2019), by using the TRE-RFP
reporter that confers transcriptional activation in response to JNK
signalling (Chatterjee and Bohmann, 2012; Jemc et al., 2012; Ruan
et al., 2016). To study the temporal activation of the JNK pathway,
and to uncover the order of the signalling events in GB, we took
advantage of another standard JNK reporter, puc-LacZ. We chose to
use this reporter because it is more specific and it is activated earlier
than the TRE-RFP reporter (Langen et al., 2013;Martin-Blanco et al.,
1998). To control the temporal induction of the tumour, we used the
thermo sensitive repression system Gal80TS. Individuals maintained
at 17°C do not activate the expression of the UAS constructs, after
larvae were switched to 29°C, the protein Gal80TS was not longer
able to repress Gal4 system and the genetic induction of GB was
activated. In addition, GB cells were marked with RFP (UAS-myr-
RFP) to distinguish GB cells and healthy tissue.
We analysed JNK activity in GB at two time points, 2 and 4 days
after GB induction. Puc-LacZ reporter signal revealed by anti-bGal
staining shows activation of the JNK pathway throughout the brain.
We quantified the b-Galactosidase ( puc-LacZ) signal that overlaps
with the glial population (RFP). The analysis of confocal images
showed that 22% of the bGal signal localised in glial cells and puc-
LacZ is mostly activated in the tissue surrounding the glial
population (∼78%) in control brains (Fig. 4A). 2 days after GB
induction, puc-LacZ activation in healthy tissue surrounding GB
cells is reduced (∼37%) and GB cells show a progressive activation
of the JNK reporter: from 63% of puc-LacZ signal in GB (2 days), to
∼80% (4 days) (Fig. 4B–D). These results suggest that the JNK
pathway is progressively activated in GB cells as the tumour
progresses.
Timeline: GB first causes neurodegeneration, and then TMs
infiltration and cell number increase
The previous results indicate that JNK signalling pathway activation
is progressive, and therefore GB progression follows a chronogram.
To evaluate the cellular events associated with GB (progressive
growth of the glial membrane projections and the number of glial
cells); we dissected larval brains at 1, 2 and 3 days after tumour
induction (referred to as 1D, 2D or 3D in Fig. 5A–C). GB TMs were
visualised with UAS-myr-RFP and the glia nuclei were stained with
a specific anti-Repo antibody to quantify the total glial cell number
(Fig. 5A–C).
The statistical analysis of glial membrane volume quantifications
(Fig. 5D) shows no significant differences in the volume of the
network between 1 day and 2 days of tumour induction.
Nevertheless, there is a significant increase in the volume of the
TMs between 2 and 3 days of tumour induction. Similarly, the
statistical analysis of the number of glial cells (Fig. 5E) shows no
significant increase in the number of glial cells between day 1 and
day 2, but there is a significant increase between day 2 and day 3,
and between day 1 and day 3 after tumour induction. This suggests a
progressive growth and expansion of the glial TMs and a
progressive increase in the number of GB cells.
To evaluate the impact of the progressive GB growth and
membrane expansion on the surrounding cells, we studied synapses
in the motor neurons. In the Drosophila larvae, motor neurons are
localised in the CNS and project their axons towards the
neuromuscular junction (NMJ), a well-established system to
evaluate neurodegeneration (Keshishian et al., 1996; Portela et al.,
2019). A great advantage of these stereotyped neurons is the
possibility of counting, rather than estimating, the number of
synapses. We are focused on the early stages of neurodegeneration,
hence the interest in documenting synapse loss rather than neuronal
death, which is a later event in a neurodegenerative process.
We quantified the number of synapses in the NMJ of third-instar
larvae after 1, 2 and 3 days of GB induction. NMJs were stained
with anti-bruchpilot to visualise active zones (synapses) (Fig. 6A–
C). The statistical analysis of synapse number (Fig. 6D) show
progressive synapse loss between 1 and 2 days, and between 2 and 3
days of tumour induction. The overall loss of synapses at the NMJ is
highly significant (Fig. 6D).
To determine whether there is an association between the
volume of the glial network and the number of synapses at the
NMJ, we plotted the number of synapses against the volume of the
glial network in a correlation graph (Fig. 6E). The correlation
index is −0.966 (3 s.f.) indicating a negative association between
the volume of the TMs and the number of synapses at the NMJ.
Therefore, larger glial TMs network correlates with a greater
synapse loss.
Our previous results indicate that GB cells increase the physical
interaction with neuronal membranes (Portela et al., 2019), this
cellular interaction is required for neuronal Wg depletion by GB,
which causes synapse loss. Moreover, the prevention of TMs
expansion or Wg depletion prevents GB cell number increase, GB
progression and synapse loss. In addition, our new results show that
neurodegeneration and GB volume expansion occurs prior to cell
number increase. Cell-to-cell communication therefore gains a
particular relevance for GB development and progression.
Taking all these data together, we propose that the
communication between GB cells and neurons is relevant for this
disease, and must play a role in the initial steps of GB before cell
proliferation (Fig. 7). Therefore, these results bring the study of cell-
to-cell communication as a relevant mechanism for GB.
Fig. 2. Egr re-localises from neuron to glia and its receptor Grindelwald
is accumulated in GB. (A,B) In silico analysis of the data from the TCGA
dataset from GlioVis (http://gliovis.bioinfo.cnio.es/) showing that TNFSF12 is
highly upregulated in several tumours of the CNS of glial origin, including GB
(grade IV), the statistical analysis extracted from the database is shown in
the table below the graph (A). In silico analysis of TCGA data indicating the
survival of patients with high or low TNFSF12 expression. Upper graph
shows the upper quartile and the graph below shows the lower quartile (B).
(C–J′) Brains from third-instar larvae. Glia are labelled with UAS-Ihog-RFP
(gray or red in the merge) driven by repo-Gal4 to visualise active cytonemes/
TM structures in glial cells. Egr protein is visualised by GFP staining (green)
of a transgenic Drosophila line in which the endogenous egr gene is GFP
tagged (Egr-GFP protein fusion reporter). (C,D) In control brain sections,
30% of Egr-GFP (gray or green in the merge) signal localised in glial cells
while most Egr-GFP signal (70%) localised in the surrounding cells that are
in close contact with glial cells. (E–G) In glioma brain sections, Egr-GFP
(green) signal shifts and 50% of the GFP signal localised in glioma cells and
the remaining 50% localised in the healthy surrounding cells. Higher
magnification image of a glioma brain section is shown in (G).
(H) Quantification of the percentage of Egr-GFP localised in glial cells in
control and glioma samples. (I,J) Grnd staining (gray or green in the merge)
in control and glioma samples. (K) Quantification of the Grnd pixel intensity
in control and glioma samples. Nuclei are marked with DAPI (blue).
(L) qPCRs with RNA extracted from control and glioma larval brains showing
a twofold increase of the transcription (mRNA levels) of egr. Data from two
independent experiments, n>10 samples analysed for each genotype per
experiment. Two-tailed t-test with Welch’s correction. Error bars show mean
±s.d.; * P<0.05, ***P≤0.0001. Scale bar size is indicated in all figures. The
expression system was active, and the GB induced, during the whole
development including both embryonic and larval stages in all experiments
in this figure. Genotypes: (C,D) Egr-GFP; repo-Gal4, ihog-RFP/UAS-lacZ;
(E,F) UAS-dEGFRλ, UAS-dp110CAAX;Egr-GFP; repo-Gal4, UAS-ihog-RFP;
(G) UAS-dEGFRλ, UAS-dp110CAAX; Gal80ts; Egr-GFP; repo-Gal4,
myr-RFP; (I) repo-Gal4, ihog-RFP/UAS-lacZ; (J) UAS-dEGFRλ,
UAS-dp110CAAX;; repo-Gal4, UAS-ihog-RFP.
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Fig. 3. Egr expressed in healthy tissue activates JNK in GB. (A–F) Larval brain sections with glial membrane projections labelled in gray (red in the
merge) and glial cell nuclei stained with Repo (gray, green in the merge). (A,B) GB brains show an increase in the number of glial cells and the volume of the
TM network compared to control brains. (C,D) egr knockdown specifically in GB cells (using two different egr-RNAi lines) did not prevent GB cell number
increase nor GB TM volume expansion. (E,F) Whole brain egr knockout in both GB cells and surrounding healthy tissue (egr−/−) prevented GB cell number
increase and TM volume expansion. (G,H) The number of Repo+ cells is quantified in panel (G) and glial/glioma network volumes are quantified in (H).
Nuclei are marked with DAPI (blue). Scale bar size is indicated in all figures. n=2 independent experiments, n>5 samples analysed for each genotype per
experiment. One-way ANOVA with Bonferroni post-hoc test. Error bars show mean±s.d.; ***P<0.0001 or ns for non-significant. The expression system was
active, and the GB induced, during the whole development including both embryonic and larval stages in all experiments in this figure. Genotypes:
(A) repo-Gal4, myr-RFP/UAS-lacZ; (B) UAS-dEGFRλ, UAS-dp110CAAX;; repo-Gal4, myr-RFP; (C) UAS-dEGFRλ, UAS-dp110CAAX;; UAS-egr-RNAi;
repo-Gal4, myr-RFP; (D) UAS-dEGFRλ, UAS-dp110CAAX;; repo-Gal4, myr-RFP/UAS-egr-RNAi; (E) egr-/egr-; repo-Gal4, myr-RFP; (F) UAS-dEGFRλ,
UAS-dp110CAAX; egr−/egr−; repo-Gal4, myr-RFP.
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DISCUSSION
Activating mutations in EGFR and PI3K pathways are the most
frequent initial signals in GB. However, the attempts to treat GB
reducing the activation of these pathways have so far been limited.
GB cells show a high mutation rate and usually present several sub-
clones within the same patient and from the same primary tumour
(McGranahan and Swanton, 2017; Qazi et al., 2017). The current
literature suggest that a multiple approach is required to obtain better
results (Prasad et al., 2011; Taylor et al., 2012;Westhoff et al., 2014;
Westphal et al., 2017; Zhao et al., 2017), and we propose that the
communication between GB and the surrounding healthy tissue is a
central mediator of tumour progression.
Progressive tumour growth
Although there is an overall significant expansion in volume of the
glial TMs membrane and an increase in the number of glial cells in
theDrosophilamodel of GB, there is no early significant increase in
those parameters. Tumour volume shows values above the average
after 2 days of tumour induction, and a great dispersion in the
volume of the network and the number of glial cells after 3 days of
tumour induction. Previous publications show that under
physiological conditions, there is a stable state that prevents cells
from exiting the cell cycle, dividing or activating the actin
cytoskeleton to extend further a network of membrane projections
(Portela et al., 2019; Read et al., 2009). Therefore, after 1 day of
tumour induction, GB cells do not show evident changes, there is a
uniform range of values for the volume of membrane projections
and number of glial cells. After 2 days of tumour induction, some
individuals abandon this stable state and GB cells extend larger and
longer membrane projections, although most individuals continue
in stability and display morphological characteristics similar to
control samples. However, after 3 days of tumour induction there is
a great expansion of membrane projections and the number of glial
cells is increased. Similar to GB patients, some individuals are more
resistant than others to the loss of homeostasis, which would explain
the variance in the values for network volume and number of glial
cells after 3 days of tumour induction.
Progressive neurodegeneration
There is a significant progressive decrease in the number of
synapses at the NMJ. Nevertheless, the variance in the number of
synapses after 1 day of tumour induction is very large, reaching
uniform values after 2 and 3 days of tumour induction. The
individuals show different resistances to the changes caused by the
GB. After 1 day of tumour induction, some individuals are
significantly affected by the tumour and suffer a great loss of
synapses at the NMJ while other individuals are more resistant, and
the number of synapses remains normal. After 2 days of tumour
induction, the impact of GB causes severe changes to all individuals
regardless of their initial resistance.
We have observed a negative correlation between the volume of
the membrane network and the number of synapses at the NMJ,
suggesting that the expansion of the membrane projections is
responsible for the neurodegeneration. Previous studies from our
laboratory have proved that TMs surround neurons and deplete
WNT from them (Portela et al., 2019), which leads to synapse loss
and neurodegeneration (Rich and Bigner, 2004). We can conclude
that as the tumour progresses, TMs grow progressively, infiltrate in
the brain and surround neurons leading to their degeneration, the
process previously described as vampirization (Portela et al., 2019).
The three main events described here do not occur concomitantly,
the progressive neurodegeneration is an earlier event in GB
development, associated to early neuronal Wg/WNT depletion by
GB cells. The expansion of the membrane network of TMs is slow
during the first 24 h of tumour development but increases after 48 h.
TMs expansion and infiltration require Wg/WNT and JNK/MMPs
Fig. 4. JNK signalling pathway activation in GB. Larval brain sections
from third-instar larvae displayed at the same scale. Glial cell bodies and
membranes are labelled with UAS-myr-RFP (gray or red in the merge)
driven by repo-Gal4 (A–C) JNK signalling pathway reporter puc-lacZ
(stained with anti-bGal, gray or green in the merge) in (A) control, (B) glioma
induced for 2 days (2D) and (C) glioma induced for 4 days (4D). (A) puc-lacZ
reporter signal revealed by bGal staining shows activation of the JNK
pathway throughout the brain. 22% of the bGal signal localised in glial cells
and most of the signal (78%) localised in the surrounding tissue in control
brains. (B,C) puc-lacZ reporter bGal signal shows a progressive activation in
GB cells, from 63% after 2 days of GB induction (B) to 80% after 4 days of
GB induction (C). (D) Quantification of the % of cells with puc-lacZ activation
in glial cells and in the surrounding tissue. Nuclei are marked with DAPI
(blue). n=2 independent experiments, n=8 samples analysed for each
genotype per experiment. One-way ANOVA with Bonferroni post-hoc test.
Error bars show mean±s.d.; **P<0.001, ***P<0.0001. Scale bar size is
indicated in all figures. The expression system was active, and the GB
induced, during the whole development including both embryonic and larval
stages in panel A. In panels B and C animals were raised at 17°C, shifted to
29°C for 2 or 4 days at ∼6 or 2 days after egg laying (AEL), respectively.
Genotypes: (A) Gal80ts/repo-Gal4, myr-RFP/puc-lacZ; (B,C) UAS-dEGFRλ,
UAS-dp110CAAX; Gal80ts; repo-Gal4, myr-RFP/puc-lacZ.
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pathways activation. Consequently, TMs expansions facilitate GB
cells to further contact and communicate with the surrounding
tissue. Eventually, Wg/WNT and JNK signals promote the increase
in the number of GB cells that occurs as a later event. These
evidences indicate that GB-neuron interaction is an earlier event
required for GB progression. Consistent with this, a recent study in
Drosophila, showed inter-tissue communication between epithelial
tumoural cells and the adjacent healthy mesenchymal cells. The
tumoural epithelial cells upregulate and transport the Notch ligand
Delta in cytonemes, which contact and communicate with the
healthy mesenchymal cells to activate Notch signalling in a non-
autonomous manner. Notch activity keep the mesenchymal cell
precursors in an undifferentiated and proliferative state that is
critical to sustain tumour progression (Boukhatmi et al., 2020). This
cell to cell interaction goes in line with our findings in glia–neuron
communication in GB, where glial cells use cytonemes/TMs to
retrieve Egr from the surrounding healthy tissue and activate JNK
signalling in the tumour cells to sustain tumour progression.
Progressive activation of JNK pathway via Egr/Grnd
In this manuscript, we expand our knowledge regarding cell to cell
communication to JNK signalling pathway. One of the main
Fig. 5. GB TM network volume and number of glial cells after 1, 2 and 3 days of tumour induction. Larval brain sections from third-instar larvae at
several magnifications (A–C) show whole brains, (A′–C‴) show single brain hemispheres. Glial cell bodies and membranes are labelled with UAS-myr-RFP
(red) driven by repo-Gal4 and glial cell nuclei are stained with Repo (green) and visualised as green spots. The insets of the red channel in (A″–C″) show
higher magnifications for a detailed visualisation of the glioma network of TMs. (A) Third-instar larval brain after 1 day of tumour induction. (B) Third-instar
larval brain after 2 days of tumour induction. (C) Third-instar larval brain after 3 days of tumour induction. (D) Quantification of the/glioma network volumes
after induction of the glioma for 1, 2 or 3 days. (E) Quantification of the number of Repo+ cells after induction of the glioma for 1, 2 or 3 days. Nuclei are
marked with DAPI (blue). Scale bar size is indicated in all figures. n=3 independent experiments, n>10 samples analysed for each timepoint per experiment.
One-way ANOVA with Bonferroni post-hoc test. Error bars show mean±s.d.; *P≤0.05; **P≤0.01; n.s., not significant. Animals were raised at 17° C, shifted to
29°C for 1, 2 or 3 days at ∼8, 6 or 4 days AEL, respectively. Genotypes: (A-C) UAS-dEGFRλ, UAS-dp110CAAX; Gal80ts; repo-Gal4, myr-RFP.
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molecular events in GB is the activation of JNK signalling that
regulates MMPs expression, TMs expansion and infiltration.
Previous results indicate that JNK pathway responds to Wg and
TMs network expansion. We described these three events as a
regulatory positive feedback loop in GB progression (Portela et al.,
2019). However, the signals that specifically activate JNK pathway
are under debate. Grnd is a receptor that upon binding to the ligand
Egr activates JNK pathway (Fig. 7). The qPCR results and the
localisation analysis of Egr-GFP fused protein suggest that Egr is
produced in the healthy surrounding tissue. The genetic knockdown
of egr in GB cells does not rescue cellular features such as the TM
network volume and GB cell number, or the lethality caused by the
GB. However, when a GB is induced in an egr somatic mutant
background (egr−/−) the tumour does not grow (Fig. 3E,F).
Therefore, if egr expression in GB cells is not relevant for GB, but
egr is upregulated in GB brain samples and egr knockout prevents
TM network expansion and GB cell number increase, these data
suggest that the main source of Egr is not the GB but the
surrounding healthy tissue. However, further analysis will be
required to investigate the contribution of autonomous Egr
production to the morphology of the GB expansion. Under
physiological conditions, a fraction of Egr is found in glial cells.
However, under GB conditions there is an increase of Egr
accumulated in the membrane of GB cells in contact with healthy
Fig. 6. Number of synapses at the NMJ of third-instar larvae after 1, 2 and 3 days of tumour induction. Neurons from the larval NMJ stained with
Bruchpilot (NC82) show the synaptic active zones. The synaptic connexions at the NMJ of Drosophila larvae are between muscles six and seven in the third
and fourth abdominal segments. Anti-Bruchpilot (α-NC82) binds to Bruchpilot marking presynaptic zones in green. Anti-Hrp marks the neuron membrane in
blue. Glial cell bodies and membranes are labelled with UAS-myr-RFP (red) driven by repo Gal4. (A) Third-instar larval NMJ after 1 day of tumour induction.
(B) Third-instar larval NMJ after 2 days of tumour induction. (C) Third-instar larval NMJ after 3 days of tumour induction. (D) Graphical representation of the
number of synapses at the NMJ after 1, 2 or 3 days of GB induction. Scale bar size is indicated in all figures. n=3 independent experiments, n>10 samples
analysed for each timepoint per experiment. One-way ANOVA with Bonferroni post-hoc test. Error bars show mean±s.d.; ***P≤0.001; * P≤0.05. (E) Scatter
plot showing the correlation between volume of the TMs network from Fig. 5D and number of synapses at the NMJ (Fig. 6D). There is a negative correlation
between the volume of the network and the number of synapses, therefore, at smaller volumes of glial network there are more synaptic connexions at the
NMJ and as the TM network volume increases, more synapses are lost. Animals were raised at 17°C, shifted to 29°C for 1, 2 or 3 days at ∼8, 6 or 4 days
AEL, respectively. Genotypes: (A–C) UAS-dEGFRλ, UAS-dp110CAAX; Gal80ts; repo-Gal4, myr-RFP.
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neuronal tissue. The progressive activation of JNK pathway in glial
cells correlates with the morphological changes (membrane
network expansion and number of glial cells) that GB cells
undergo after 2 days of tumour induction. Therefore, this example
of neuron-GB interaction where non-autonomous signals facilitate
tumour progression and GB-mediated neurodegeneration,
contributes to the complexity and versatility of these incurable
tumours and highlights the relevance of the interactions and
signalling between GB and the surrounding healthy tissue (Fig. 7).
Therefore, it is of interest to uncover the regulatory mechanisms that
mediate egr expression and secretion in neurons in response to GB
induction, and the associated response in GB cells mediated by
Grnd/Egr as a potential modulator of GB progression.
MATERIALS AND METHODS
Fly stocks
Flies were raised in standard fly food at 25°C. Fly stocks from the
Bloomington stock Centre: UAS-lacZ (BL8529), UAS-myr-RFP (BL7119),
repo-Gal4 (BL7415), tub-gal80ts (BL7019), Egr-GFP (BL66381), UAS-
egr-RNAi 2 (BL 55276) and UAS-egr-RNAi 3 (BL58993), egr[MI15372]
(BL59754), dnab-Gal4, UAS-CD8-GFP (gift from L. Y. Cheng), UAS-
dEGFRλ, UAS-PI3K92E (dp110CAAX) (gift from R. Read), UAS-ihog-RFP
(gift from I. Guerrero), puc-lacZ (gift from E. Martín-Blanco), UAS-dmyc
(Moreno and Basler, 2004), UAS-TOR-DERCA (Domínguez et al., 1998).
Drosophila glioblastoma model
In Drosophila, a combination of EGFR and PI3K mutations effectively
causes a glioma-like condition that shows features of human gliomas
including glia expansion, brain invasion, neuron dysfunction, synapse loss
and neurodegeneration (Kegelman et al., 2014; Portela et al., 2019; Read,
2011; Read et al., 2009). To generate a glioma in Drosophilamelanogaster,
the Gal4/UAS system (Brand and Perrimon, 1993) was used as described
above (repo-Gal4>UAS-EGFRλ, UAS-dp110CAAX). The expression system
was active during the whole development including both embryonic and
larval stages in all experiments in Figs 1–3 and Fig. S1. To restrict the
expression of this genetic combination and control it in a temporal manner,
we used the thermo-sensitive repression system Gal80TS. Individuals
maintained at 17°C did not activate the expression of the UAS constructs,
but when the larvae were switched to 29°C, the protein Gal80TS changed
conformation and was not longer able to bind to Gal4 to prevent its
interaction with UAS sequences, and the expression system was activated
and therefore the GB was induced. This system was used in all experiments
in Figs 4–6. Tub-GAL80TS; repo-Gal4>UAS-EGFRλ, UAS-dp110CAAX
animals were raised at 17°C, shifted to 29°C for 1, 2, 3 or 4 days at ∼8, 6, 4
or 2 days AEL, respectively, and subjected to dissection immediately after.
Antibodies for immunofluorescence
Third-instar larval brains were dissected in phosphate-buffered saline
(PBS), fixed in 4% formaldehyde for 30 min, washed in PBS+0.1 or 0.3%
Triton X-100 (PBT), and blocked in PBT+5% BSA.
Antibodies used were as follows: mouse anti-Wg [Developmental Studies
Hybridoma Bank (DSHB) 4D4 1:50 (Brook and Cohen, 1996)], mouse anti-
Repo [DSHB 8D12 1:50 (Stork et al., 2014)], mouse anti-Fz1 [DSHB 1C11
1:50 (Park et al., 1994)], mouse anti-Cyt-Arm [DSHB N27A1 1:50
(Riggleman et al., 1990)], mouse anti-MMP1 [DSHB 5H7B11, 3A6B4,
3B8D12, 1:50 (Page-McCaw et al., 2003)], rabbit anti-MMP2 [1:500, (Dear
et al., 2016)], guinea pig anti-Grnd [1:250 (Andersen et al., 2015)], mouse
anti-β-galactosidase [Sigma-Aldrich G4644, 1:500 (Portela et al., 2019)],
Fig. 7. Cell to cell communication mediate GB progression in Drosophila. Glioma cells produce a network of TMs that grow to reach the surrounding
tissue that includes neurons. Grnd is increased in the GB TMs and Egr is produced in the surrounding tissue. Egr activates the JNK signalling pathway
through Grnd in GB. As a consequence, MMPs are upregulated in GB and facilitate further TM infiltration in the brain that is necessary for synapse loss in the
surrounding neurons and GB cell number increase. This results in tumour progression and lethality.
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mouse anti-GFP [Invitrogen A11120, 1:500 (Djiane et al., 2005)], mouse
anti-bruchpilot [DSHB nc82, 1:20 (Wagh et al., 2006)], Rabbit anti-Hrp
[Jackson ImmunoResearch 111-035-144, 1:400 (Stork et al., 2014)].
Secondary antibodies: anti-mouse Alexa 488, 568, 647, anti-rabbit Alexa
488, 568, 647 (Thermo Fisher Scientific, 1:500). DNAwas stained with 2-
(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI, 1 µM).
qRT-PCRs
Total RNAwas isolated from larvae brains (Trizol, Invitrogen), and cDNAs
were synthesised with M-MLV RT (Invitrogen).
qRT-PCR was performed using a 7500 Real Time PCR System (Applied
Biosystems) with cycling conditions of 95°C for 10 min and 40 cycles of
95°C for 15 s and 55°C for 1 min. Each experimental point was performed
with samples from two independent crosses and three replicates per
experimental point. Results were normalised using the housekeeping Rp49
and the ΔΔ cycle threshold method and are expressed as the relative change
(-fold) of the stimulated group over the control group, which was used as a
calibrator.
qRT-PCR results were analysed with 7500 version 2.0.6 software
(Applied Biosystems). grnd and egr qRT-PCRs were performed using






Fluorescent labelled samples were mounted in Vectashield mounting media
with DAPI (Vector Laboratories) and analysed by confocal microscopy
(LEICA TCS SP5). In all experiments the whole brain lobes were acquired
individually and whole stacks were analysed. The images shown in the
figures are a single plane images to facilitate visualisation. In some panels,
higher magnifications of single plane images are shown in the figures to
facilitate the visualisation of the antibody stainings in more detail. Images
were processed using Leica LAS AF Lite and Fiji (Image J 1.50e). Images
were assembled using Adobe Photoshop CS5.1.
Quantifications
Relative MMP1 and Grnd staining within brains was determined from
images taken at the same confocal settings. Average pixel intensity was
measured using measurement log tool from Fiji 1.51g and Adobe Photoshop
CS5.1. Average pixel intensity was measured in the glial tissue and in the
adjacent healthy tissue and expressed as a ratio. Glial network volume was
quantified using Imaris surface tool (Imaris 6.3.1 Bitplane Scientific
Solutions software).
The number of Repo+ cells, the number of synaptic active sites and the
number of puc-lacZ positive cells was quantified by using the spots tool
Imaris 6.3.1 software, we selected a minimum size and threshold for the
puncta in the control samples of each experiment. Then we applied these
conditions to the analysis of each corresponding experimental sample. For
the puc-lacZ glia or healthy surrounding tissue co-localisation studies we
quantified the total number of puc-lacZ+ cells and then applied a co-
localisation filter (intensity centre of the channel of interest) using the Spots
tool from the Imaris 6.3.1 software.
For the co-localisation of Egr-GFP in glial cells, GFP channel volume
was quantified using Imaris surface tool.We selected a specific threshold for
the total volume in the control samples and then we applied these conditions
to the analysis of the corresponding experimental sample. Then we applied a
co-localisation filter (intensity mean of the red channel).
Statistical analysis
To analyse and plot the data, we used GraphPad Prism 6. We performed a
D’Agostino & Pearson normality test and the data found to have a normal
distribution were analysed by a two-tailed t-test with Welch-correction. In
the case of multiple comparisons, we used a one-way ANOVA with
Bonferroni post-hoc test. The data that did not pass the normality test were
subjected to a two-tailed Mann–Whitney U-test or in the case of multiple
comparisons a Kruskal–Wallis test with Dunn’s post-hoc test. Error bars
represent standard error of the mean. * represents P-value≤0.05;
**P-value≤0.01; ***P-value≤0.001. Statistical values of P-value >0.05
were not considered significant, (n.s.).
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Casas-Tintó, S. and Portela, M. (2019). Cytonemes, their formation, regulation,
and roles in signaling and communication in tumorigenesis. Int. J. Mol. Sci. 20,
5641. doi:10.3390/ijms20225641
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Doupé, D. P., Marshall, O. J., Dayton, H., Brand, A. H. and Perrimon, N. (2018).
Drosophila intestinal stem and progenitor cells aremajor sources and regulators of
homeostatic niche signals. Proc. Natl. Acad. Sci. USA 115, 12218-12223. doi:10.
1073/pnas.1719169115
Feng, J., Yan, P.-F., Zhao, H.-Y., Zhang, F.-C., Zhao, W.-H. and Feng, M. (2016).
Inhibitor of nicotinamide phosphoribosyltransferase sensitizes glioblastoma cells
to temozolomide via activating ROS/JNK signaling pathway. Biomed. Res. Int.
2016, 1450843. doi:10.1155/2016/1450843
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A.,
Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C. et al. (2007). Malignant
astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21,
2683-2710. doi:10.1101/gad.1596707
Gallego, O. (2015). Nonsurgical treatment of recurrent glioblastoma. Curr. Oncol.
22, e273-e281. doi:10.3747/co.22.2436
Hagemann, T., Wilson, J., Kulbe, H., Li, N. F., Leinster, D. A., Charles, K.,
Klemm, F., Pukrop, T., Binder, C. and Balkwill, F. R. (2005). Macrophages
induce invasiveness of epithelial cancer cells via NF-κB and JNK. J. Immunol.
175, 1197-1205. doi:10.4049/jimmunol.175.2.1197
Hagemann, C., Anacker, J., Haas, S., Riesner, D., Schömig, B., Ernestus, R.-I.
and Vince, G. H. (2010). Comparative expression pattern of Matrix-
Metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC
Res. Notes 3, 293. doi:10.1186/1756-0500-3-293
Hagemann, C., Anacker, J., Ernestus, R. I. and Vince, G. H. (2012). A complete
compilation of matrix metalloproteinase expression in human malignant gliomas.
World J. Clin. Oncol. 3, 67-79. doi:10.5306/wjco.v3.i5.67
Hayden, E. C. (2010). Genomics boosts brain-cancer work.Nature 463, 278. doi:10.
1038/463278a
Holland, E. C. (2000). Glioblastoma multiforme: the terminator. Proc. Natl. Acad.
Sci. USA 97, 6242-6244. doi:10.1073/pnas.97.12.6242
Hsu, J. B.-K., Chang, T.-H., Lee, G. A., Lee, T.-Y. and Chen, C.-Y. (2019).
Identification of potential biomarkers related to glioma survival by gene expression
profile analysis. BMC Med Genomics 11, 34. doi:10.1186/s12920-019-0479-6
Huang, C., Rajfur, Z., Borchers, C., Schaller, M. D. and Jacobson, K. (2003). JNK
phosphorylates paxillin and regulates cell migration. Nature 424, 219-223. doi:10.
1038/nature01745
Igaki, T., Kanda, H., Yamamoto-Goto, Y., Kanuka, H., Kuranaga, E., Aigaki, T.
andMiura, M. (2002). Eiger, a TNF superfamily ligand that triggers the Drosophila
JNK pathway. EMBO J. 21, 3009-3018. doi:10.1093/emboj/cdf306
Ispanovic, E. and Haas, T. L. (2006). JNK and PI3K differentially regulate MMP-2
and MT1-MMP mRNA and protein in response to actin cytoskeleton
reorganization in endothelial cells. Am. J. Physiol. Cell Physiol. 291,
C579-C588. doi:10.1152/ajpcell.00300.2005
Jarabo, P., de Pablo, C., Herranz, H., Martin, F. A., Casas-Tinto, S. (2020). Insulin
signaling mediates neurodegeneration in glioma. bioRxiv; 894469. doi:10.1101/
2020.01.03.894469
Jemc, J. C., Milutinovich, A. B., Weyers, J. J., Takeda, Y. and Van Doren, M.
(2012). raw Functions through JNK signaling and cadherin-based adhesion to
regulate Drosophila gonadmorphogenesis.Dev. Biol. 367, 114-125. doi:10.1016/
j.ydbio.2012.04.027
Kahlert, U. D., Suwala, A. K., Koch, K., Natsumeda, M., Orr, B. A., Hayashi, M.,
Maciaczyk, J. and Eberhart, C. G. (2015). PharmacologicWnt inhibition reduces
proliferation, survival, and clonogenicity of glioblastoma cells. J. Neuropathol.
Exp. Neurol. 74, 889-900. doi:10.1097/NEN.0000000000000227
Kamino, M., Kishida, M., Kibe, T., Ikoma, K., Iijima, M., Hirano, H., Tokudome,
M., Chen, L., Koriyama, C., Yamada, K. et al. (2011). Wnt-5a signaling is
correlated with infiltrative activity in human glioma by inducing cellular migration
and MMP-2. Cancer Sci. 102, 540-548. doi:10.1111/j.1349-7006.2010.01815.x
Kegelman, T. P., Hu, B., Emdad, L., Das, S. K., Sarkar, D. and Fisher, P. B.
(2014). In vivo modeling of malignant glioma: the road to effective therapy. Adv.
Cancer Res. 121, 261-330. doi:10.1016/B978-0-12-800249-0.00007-X
Keshishian, H., Broadie, K., Chiba, A. and Bate, M. (1996). The drosophila
neuromuscular junction: a model system for studying synaptic development and
function. Annu. Rev. Neurosci. 19, 545-575. doi:10.1146/annurev.ne.19.030196.
002553
Kitanaka, C., Sato, A. and Okada, M. (2013). JNK signaling in the control of the
tumor-initiating capacity associated with cancer stem cells. Genes Cancer 4,
388-396. doi:10.1177/1947601912474892
Klaus, A. andBirchmeier, W. (2008). Wnt signalling and its impact on development
and cancer. Nat. Rev. Cancer 8, 387-398. doi:10.1038/nrc2389
LaFever, K. S., Wang, X., Page-McCaw, P., Bhave, G. and Page-McCaw, A.
(2017). Both Drosophila matrix metalloproteinases have released andmembrane-
tethered forms but have different substrates. Sci. Rep. 7, 44560. doi:10.1038/
srep44560
Langen, M., Koch, M., Yan, J., De Geest, N., Erfurth, M.-L., Pfeiffer, B. D.,
Schmucker, D., Moreau, Y. and Hassan, B. A. (2013). Mutual inhibition among
postmitotic neurons regulates robustness of brain wiring in Drosophila. Elife 2,
e00337. doi:10.7554/eLife.00337
Lee, Y.-S., Lan Tran, H. T. and Van Ta, Q. (2009). Regulation of expression of
matrix metalloproteinase-9 by JNK in Raw 264.7 cells: presence of inhibitory
factor(s) suppressing MMP-9 induction in serum and conditioned media. Exp.
Mol. Med. 41, 259-268. doi:10.3858/emm.2009.41.4.029
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger,
D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P. and Ellison, D. W.
(2016). The 2016World Health Organization classification of tumors of the central
nervous system: a summary. Acta Neuropathol. 131, 803-820. doi:10.1007/
s00401-016-1545-1
Lowy, A. M., Clements, W. M., Bishop, J., Kong, L., Bonney, T., Sisco, K.,
Aronow, B., Fenoglio-Preiser, C. and Groden, J. (2006). β-Catenin/Wnt
signaling regulates expression of the membrane type 3 matrix
metalloproteinase in gastric cancer. Cancer Res. 66, 4734-4741. doi:10.1158/
0008-5472.CAN-05-4268
Lyu, J. and Joo, C.-K. (2005). Wnt-7a up-regulates matrix metalloproteinase-12
expression and promotes cell proliferation in corneal epithelial cells during wound
healing. J. Biol. Chem. 280, 21653-21660. doi:10.1074/jbc.M500374200
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee,
W. K. and DePinho, R. A. (2001). Malignant glioma: genetics and biology of a
grave matter. Genes Dev. 15, 1311-1333. doi:10.1101/gad.891601
Malemud, C. J. (2006). Matrix metalloproteinases (MMPs) in health and disease: an
overview. Front. Biosci. 11, 1696-1701. doi:10.2741/1915
Martin-Blanco, E., Gampel, A., Ring, J., Virdee, K., Kirov, N., Tolkovsky, A. M.
and Martinez-Arias, A. (1998). puckered encodes a phosphatase that mediates
a feedback loop regulating JNK activity during dorsal closure in Drosophila.Genes
Dev. 12, 557-570. doi:10.1101/gad.12.4.557
Matsuda, K., Sato, A., Okada, M., Shibuya, K., Seino, S., Suzuki, K., Watanabe,
E., Narita, Y., Shibui, S., Kayama, T. et al. (2012). Targeting JNK for therapeutic
depletion of stem-like glioblastoma cells. Sci. Rep. 2, 516. doi:10.1038/srep00516
McGranahan, N. and Swanton, C. (2017). Clonal heterogeneity and tumor
evolution: past, present, and the future. Cell 168, 613-628. doi:10.1016/j.cell.
2017.01.018
McGuire, S. (2016). World Cancer Report 2014. Geneva, Switzerland:World Health
Organization, International Agency for Research on Cancer, WHO Press, 2015.
Adv. Nutr. 7, 418-419. doi:10.3945/an.116.012211
Miller, J. J., Shih, H. A., Andronesi, O. C. and Cahill, D. P. (2017). Isocitrate
dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Cancer 123, 4535-4546. doi:10.1002/cncr.31039
Moreno, E., Basler, K. (2004). dMyc transforms cells into super-competitors. Cell
2004, Apr 2;117(1):117-29. doi:10.1016/s0092-8674(04)00262-4
Moreno, E., Yan, M. and Basler, K. (2002). Evolution of TNF signaling
mechanisms: JNK-dependent apoptosis triggered by Eiger, the Drosophila
homolog of the TNF superfamily. Curr. Biol. 12, 1263-1268. doi:10.1016/S0960-
9822(02)00954-5
Mu, N., Gu, J., Liu, N., Xue, X., Shu, Z., Zhang, K., Huang, T., Chu, C., Zhang, W.,
Gong, L. et al. (2018). PRL-3 is a potential glioblastoma prognostic marker and
promotes glioblastoma progression by enhancing MMP7 through the ERK and
JNK pathways. Theranostics 8, 1527-1539. doi:10.7150/thno.22699
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